Indolent lymphoma · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Obinutuzumab monotherapy Variant #03 | — | R 166 941 | 21d | — | — | — | — | — |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~30.8 mo | — | ~11 | ~R 69 973 PFS proxy · indirect | 2 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | 51.6 mo | — | 9 | R 468 PFS proxy | 1 |
3 of 3 regimens shown